Items Tagged ‘AML’

September 19th, 2017

Pass it On: It’s Leukemia National Awareness Month

By

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia and 24,400 deaths in 2016. For lymphoma, the ACS estimates that 81,080 new cases and 21,270 deaths will occur in the United States in […]

View full entry

Tags: all, AML, CLL, CML, Leukemia, News


September 5th, 2017

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia

By

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, AML, CD33 antigen, gemtuzumab ozogamicin, Leukemia, Mylotarg, News, Precision Cancer Medicine, targeted therapy


August 10th, 2017

FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia

By

The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the Real Time IDH2 Assay, which is used to detect specific mutations in the IDH2 […]

View full entry

Tags: Acute Myeloid Leukemia, AML, Enasidenib, Idhifa, Leukemia, News


June 20th, 2017

Precision Therapy Enasidenib Effective in Treating Acute Myeloid Leukemia

By

According to early clinical trial results published in the journal Blood, some patients with relapsed or treatment-resistant acute myeloid leukemia may achieve remission with an experimental targeted therapy. AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more […]

View full entry

Tags: 2016, Acute Myeloid Leukemia, AML, asco, blood cancer, COMFORT 1, Enasidenib, IDH2 gene, jakafi, Leukemia, myelofibrosis, News


November 17th, 2016

FDA Priority Review Granted for Midostaurin in Leukemia

By

The United States Food and Drug Administration (FDA) has granted priority review to PKC412 (midostaurin) in the treatment of newly diagnosed acute myeloid leukemia (AML) with the FLT3 mutation, as well as for the treatment of advanced systemic mastocytosis (SM). The diagnostic test to detect the FLT3 mutation has also been accepted for review by […]

View full entry

Tags: Acute Myeloid Leukemia, AML, fda, FLT3 mutation, itchy skin, Leukemia, mast cell, mastocytosis, midostaurin, News, PKC412


August 9th, 2016

Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational drug Pracinostat in combination with azacitidine for the treatment of elderly patients with newly diagnosed acute myeloid leukemia (AML). Acute myeloid leukemia (AML) is a cancer of the bone marrow (spongy portion found in the middle of bones) and blood […]

View full entry

Tags: Acute Myeloid Leukemia, AML, azacitidine, Breakthrough Therapy Designation, elderly, FDA. BTD, HDACs, Leukemia, News, Pracinostat


December 31st, 2015

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings

By

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH) Annual Meeting, in Orlando, December 5-8, made it increasingly clear that new discoveries […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, all, AML, ASH, blood cancer, CAR T, Chronic Lymphocytic Leukemia, CLL, fda, Leukemia, Lymphoma


December 30th, 2015

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML and MDS Patients Undergoing Stem Cell Transplant

By

Hematopoietic Stem Cell Transplant (SCT) is a standard and potentially curative treatment for individuals with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically only high dose myeloablative treatment regimens were utilized since they were thought necessary to eradicate the malignant cells in the bone marrow. In recent years, SCT physicians have increasingly used reduced […]

View full entry

Tags: Acute Myeloid Leukemia, Allogeneic Stem Cell Transplant, AML, General Myelodysplastic Syndrome, hematopoietic stem cell transplant, Leukemia, MDS, Myelodysplastic Syndrome, News, sct, Stem Cell Transplant


July 30th, 2015

Promising Survival for AML Patients Treated with Stem Cells from Related Half Matched Donor

By

Patients with acute myeloid leukemia (AML) may have a promising new treatment option. Research shows that stem cell transplant from a “half matched” related donor plus chemotherapy results in similar survival as a transplant from an unrelated matched donor. Further more, transplant from a half matched donor lowers the risk of graft-versus-host disease (GVHD). These […]

View full entry

Tags: Acute Myeloid Leukemia, AML, aploidentical transplant, half matched dono, Leukemia, News


January 28th, 2015

CPX-351 Receives Fast Track Designation for Secondary Acute Myeloid Leukemia in Elderly Patients

By

The U. S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigational drug CPX-351, a liposomal formulation of cytarabine-daunorubicin, for the treatment of elderly patients with secondary acute myeloid leukemia. Acute myeloid leukemia (AML) is a cancer of the bone marrow (spongy portion found in the middle of bones) and blood […]

View full entry

Tags: Acute Myeloid Leukemia, AML, cpx-351, cytaribine-dauorubicin, fda, Leukemia, News


December 8th, 2014

Orphan-drug Designation from FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

By

(OMNI-CancerConnect) Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the US Food and Drug Administration (FDA) has granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60. Actimab-A is currently in […]

View full entry

Tags: actimab-a, Acute Myeloid Leukemia, AML, Leukemia, News


August 8th, 2014

Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk

By

Thiopurines are an established treatment for inflammatory bowel disease (IBD) patients.  They are used to reduce inflammation and provide symptom relief.  Thiopurine immunosuppressive drugs have now been reported to increase the risk of acute myelod leukemia and myelodysplastic syndrome, a rare bone marrow disorder, seven-fold among IBD patients. These data were recently reported in a […]

View full entry

Tags: Acute Myeloid Leukemia, AML, cancer prevention, General Myelodysplastic Syndrome, Health and Wellness, Leukemia, MDS, Myelodysplastic Syndrome, News, Screening/Prevention Leukemia, thiopurines